The result of two clinical studies showed that the use of canagliflozine to treat type 2 diabetes mellitus, reduces 14 percent the risk of a cardiovascular and brain event (embolism).
The risk of hospitalization due to heart failure, and 40 percent, the progression of kidney disease, also reduces 33 percent, the latter the most frequent cause of diabetes complication and the one that generates the most expense to health systems.
In the 77th Scientific Session of the American Association of Diabetes (ADA), researchers at the George Institute for Global Health, presented the results of the cardiovascular evaluation studies of Canagliflozine (Canvas) and the effects of the Canagliflozine in the evaluation criteriaRenal (Canvas-R).
They explained that more than 10,000 patients from 30 countries participated in the study, including Mexico, and it was observed that the drug managed to significantly reduce the combined risk of death due to cardiovascular cause, myocardial infarction and non -fatal stroke.
The clinical trial included patients who had already had a heart attack, and who had two or more risk factors to have a first cardiovascular event.
In this way, it was shown that canagaglyzine works in secondary protection, as well as to prevent a patient from being infarcted for the first time.
At the San Diego Convention Center, Bruce Neal, principal rehearsal researcher, referred to success in the results.
"The Canvas program showed reductions consisting of all components of the primary objective (cardiovascular death, myocardial infarction and stroke), indicating the effectiveness of canagliflozine for all main cardiovascular risks that probably affect patients with diabetes," he added.
Subsequently in an interview, the Edocrinologist of the University Hospital, of the Autonomous University of Nuevo León, Fernando Lavalle, said that these promising data open new opportunities to patients with type 2 diabetes mellitus for the control of the disease.
"Patients with diabetes have a two -to -old probability of associated comorbidities such as heart failure and kidney disease, and Canvas's results demonstrate the canagliflozine potential for the risk of these conditions," he said.
The study was sponsored by the pharmaceutical Janssen and the results were published in the New England Journal of Medicine, one of the most prestigious magazines in the medical field.
